Key result
Monotherapy with aspirin or systemic anticoagulation is recommended post-TAVR due to high rates of bleeding associated with more potent and prolonged antithrombotic regimens.
Why the study?
As TAVR expands to lower-risk populations, optimizing postprocedural management and balancing thrombotic and bleeding complications has become a focus, with significant variability remaining across guidelines and institutions.
What is the optimal antithrombotic therapy after transcatheter aortic valve replacement to balance ischemic and bleeding risks?
What is the optimal antithrombotic therapy after transcatheter aortic valve replacement to balance ischemic and bleeding risks?
A conservative antithrombotic approach using aspirin or OAC monotherapy is favored post-TAVR to minimize bleeding risk without compromising ischemic protection.
No takes yet. Share an insight, caveat, or question.
Supports conservative post-TAVR antithrombotic strategy in reviews; leaves open optimal regimens pending randomized trials.
Eckstein et al. (2020) conducted a review in Severe aortic stenosis post-TAVR. Antithrombotic therapy (aspirin or OAC monotherapy) vs. Dual antiplatelet therapy (DAPT) or OAC plus antiplatelet therapy was evaluated. Monotherapy with aspirin or systemic anticoagulation is recommended post-TAVR due to high rates of bleeding associated with more potent and prolonged antithrombotic regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: